Teva might be known for its sandals, but its new Trailwinder Hiking Shoe was great for dry land trail excursions. The post ...

Or, if you don't already have a trip planned, these might just tip the scale and get you to commit. View Entire Post › ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...

Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options become available today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked ...

20.45% on placebo at Week 14. BofA raises Teva’s price target to $25, predicting $2 billion peak sales for duvakitug with profits split between Teva and its partner. In the RELIEVE UCCD study ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

Teva announced it was partnering with Sanofi to further develop duvakitug for treatment of IBD in October last year. The drug was developed by the Israeli big pharma to target TL1A (TNF superfamily ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...

Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease. The ...